Showing results (671-680 of 782) with videos related to
Sort By:
Pageof 79
Cancer Research|March 21, 2020
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple MyelomaYi Hu, Huimin Liu, Chuanfeng Fang, et al.Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.Journal of Medicinal Chemistry|February 24, 2023
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1Wenchao Lu, Yao Liu, Yang Gao, et al.Cancer Research|July 3, 2008
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivoConstantine S Mitsiades, Enrique M Ocio, Atanasio Pandiella, et al.Cancer|February 15, 2022
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.Pageof 79